Advertisement
Advertisement
U.S. markets open in 4 hours 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Xtant Medical Holdings, Inc. (XTNT)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.5400-0.0202 (-3.61%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close0.5602
Open0.5562
Bid0.5400 x 800
Ask0.0000 x 1800
Day's Range0.5400 - 0.5700
52 Week Range0.4800 - 2.3800
Volume20,627
Avg. Volume38,931
Market Cap47.149M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0890
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XTNT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xtant Medical Holdings, Inc.
    NUVA: Raising target price to $44.00NUVASIVE INC has an Investment Rating of SELL; a target price of $44.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Xtant Medical Announces First Quarter 2022 Financial Results

    BELGRADE, Mont., May 05, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2022. “By building momentum in our business, underscored by first quarter revenue growth and the progress of our key strategic growth pillars, we are pleased with the promising start to 2022,” said Sean Brown

  • GlobeNewswire

    Xtant Medical Appoints Scott Neils as Chief Financial Officer

    BELGRADE, Mont., May 02, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Chief Financial Officer, effective June 1, 2022. “Scott’s success and experience during his tenure at Xtant, including his recent position as interim Chief Financial Officer, makes him an invaluable member of our team,” said Sean Browne, Presi

  • GlobeNewswire

    Xtant Medical to Issue First Quarter 2022 Financial Results on May 5, 2022

    BELGRADE, Mont., April 28, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2022, before the open of the financial markets on Thursday, May 5, 2022. Sean Browne, President and Chief Executive Officer, and Scott Neils, Interim Chief Financial Officer, will host a confere

Advertisement
Advertisement